Diabetic macular edema

Ophthalmologica

Volumn 227, Issue SUPPL. 1, 2012, Pages 21-29

  Lang, Gabriele E ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Aflibercept; Anti VEGF; Bevacizumab; Diabetic macular edema; Pegaptanib; Ranibizumab

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; EYLEA; PEGAPTANIB; RANIBIZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ARTICLE; BLOOD RETINA BARRIER; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG EFFICACY; DRUG SAFETY; ENDOPHTHALMITIS; EUROPE; GENE OVEREXPRESSION; HUMAN; LASER COAGULATION; LOW LEVEL LASER THERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA CELL; TIGHT JUNCTION; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY; VISUAL IMPAIRMENT; VITREOUS BODY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; APTAMERS, NUCLEOTIDE; DIABETIC RETINOPATHY; HUMANS; MACULAR EDEMA; RECOMBINANT FUSION PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84860197211     PISSN: 00303755     EISSN: 14230267     Source Type: Journal    
DOI: 10.1159/000337156     Document Type: Article

References (18)

1. Lang GE, Lang SJ: Clinical treatment of diabetic macular edema. Klin Monatsbl Augenheilkd 2011; 228:R1-R11.
2. Lang GE: Pharmacological treatment of diabetic retinopathy. Ophthalmologica 2007; 221: 112-117. (Pubitemid 46465436)
3. Caldwell RB, Bartoli M, Behzadian MA, El-Remessy AEB, Al-Shabrawey M, Platt DH, Caldwell RW: Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Diabetes Metab Res Rev 2003; 19: 442-445.
4. Deissler HL, Lang GE: In vitro studies on the mechanism of action of VEGF and its inhibitors. Klin Monatsbl Augenheilkd 2008; 225: 623-628.
5. Deissler H, Deissler H, Lang S, Lang GE: VEGF-induced effects on proliferation, migration and tight junctions are restored by ranibizumab (Lucentis) in microvascular retinal endothelial cells. Br J Ophthalmol 2008; 92: 839-843. (Pubitemid 351839580)
6. Massin P, Bandello F, Garweg JG, et al: Safety and efficacy of ranibzumab in diabetic macular edema (RESOLVE Study): a 12-month randomized, controlled, doublemasked, multicenter phase II study. Diabetes Care 2010; 33: 2399-2405.
7. Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, Sutter F, Simader C, Burian G, Gerstner O, Weichselberger A, RESTORE study group: The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011; 118: 615-625.
8. Bandello F, Cunha-Vaz J, Chong NV, Lang GE, Massin P, Mitchell P, Porta M, Prünte C, Schlingemann R, Schmidt-Erfurth U: New approaches for the treatment of diabetic macular oedema: recommendations by an expert panel. Eye (Lond) 2012, DOI: 10.1038/ eye.2011.337, E-pub ahead of print.
9. Bandello F, De Benedetto U, Knutsson KA, Parodi MB, Cascavilla ML, Iacono P: Ranibizumab in the treatment of patients with visual impairment due to diabetic macular edema. Clin Ophthalmol 2011; 5: 1303-1308.
10. Nguyen QD, Shah SM, Khwaja AA, er al: Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology 2010; 117: 2146-2151.
11. Diabetic Retinopathy Clinical Research Network, Scott IU, Edwards AR, Beck RW, Bressler NM, Chan CK, Elman MJ, Friedman SM, Greven CM, Maturi RK, Pieramici DJ, Shami M, Singerman LJ, Stockdale CR: A phase 2 randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007; 114: 1860-1867.
12. Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, Ferris FL 3rd, Friedman SM, Glassman AR, Miller KM, Scott IU, Stockdale CR, Sun JK: Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010; 117: 1064-1077.
13. Elman MJ, Bressler NM, Qin H, Beck RW, Ferris FL 3rd, Friedman SM, Glassman AR, Scott IU, Stockdale CR, Sun JK, Diabetic Retinopathy Clinical Research Network: Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011; 118: 609-614.
14. Michaelides M, Kaines A, Hamilton RD, et al: A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology 2010; 117: 1078-1086.
15. Sultan MB, Zhou D, Loftus J, Dombi T, Ice KS, Macugen 1013 Study Group: A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema. Ophthalmology 2011; 118: 1107-1118.
16. Stewart MW: Aflibercept (VEGF-TRAP): the next anti-VEGF drug. Inflamm Allergy Drug Targets 2011; 10: 497-508.
17. Do DV, Schmidt-Erfurth U, Gonzalez VH, Vitti R, Rückert R, Sandbrink R, Stein D, Yang K, Beckmann K, Heier: The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema. Ophthalmology 2011; 118: 1819-1826.
18. Kakkassery V, Winterhalter S, Joussen AM: Anti-VEGF inhibitors and their role in the treatment of diabetic macular oedema. Klin Monatsbl Augenheilkd 2010; 227: 701-711.